Latest database descriptions

Primary objective : To describe in real life the glucocorticoid-sparing effect after 12 months of treatment with RoActemra® in patients with moderate to severe RA and to determine predictive factors.

Secondary objectives:
1. to describe the characteristics of the population at baseline;
2. to evaluate efficacy of RoActemra® (EULAR response and/or glucocorticoid dosage) in real life;
3. to describe therapeutic management of RA [glucocorticoids and/or conventional Disease-Modifying Anti-Rheumatic Drug(s) (DMARDs) in combination with RoActemra®];
4. to describe change in functional capacity of patients and impact of the disease on the patient over time during follow-up (HAQ-DI and RAID self-report questionnaires);
5. to assess safety of RoActemra®.

Primary objective: To describe Progression Free Survival (PFS) in patients with stage IIIB or IV squamous NSCLC initiating treatment with Tarceva® after failure of first-line platinum-based chemotherapy.

Secondary objectives:
- To describe characteristics of patients treated with Tarceva®;
- To describe Tarceva® treatment modalities in patients with squamous NSCLC after failure of first-line platinum-based chemotherapy;
- To evaluate Overall Survival (OS);
- To describe the evolution of QoL;
- To describe the safety profile of Tarceva®.

Primary objective : To describe in a real-life setting the factors influencing the use of RoActemra® as monotherapy or in combination with DMARDs in patients with rheumatoid arthritis
Secondary objectives :
- To describe the characteristics of patients treated with RoActemra® as monotherapy or in combination with another treatment.
- To describe impact of physician characteristics on use of RoActemra® as monotherapy or in combination.
- For patients on RoActemra® monotherapy, to describe reasons for discontinuation or non-use of csDMARDs.
- To evaluate treatment maintenance one year after RoActemra® initiation in a real-life setting.
- To describe efficacy of RoActemra® in real conditions of use.
- To describe effect of RoActemra® on quality of life in real conditions of use.
- To assess safety profile of RoActemra® in real conditions of use.

Primary objective : To assess the drug retention rate of TCZ sc at 12 months under real-world conditions in patients with moderate to severe active RA followed by hospital- and office-based rheumatologists
Secondary objectives :
- To assess the drug retention rate of TCZ sc at 6 and 18 months.
- To compare the drug retention of TCZ sc in monotherapy and in combination with MTX or other csDMARD.
- To describe steroid dosing after introduction of TCZ sc with a stratification on the use of MTX or other csDMARDs at 6, 12 and 18 months.
- To assess adherence to TCZ sc using a French version of the Compliance Questionnaire for Rheumatology 5 (CQR5) and patient diary at 6, 12 and 18 months.
- To evaluate the French version of the CQR5 by assessing the correlation with the data collected from the patient diary data.
- To describe the modalities of use of TCZ sc.
- To describe the management of RA and patients’ healthcare pathway between hospital- and office-based rheumatologists.
- To describe the efficacy of TCZ sc under real-world conditions of use.
- To describe the characteristics of patients treated with TCZ sc and the characteristics of the involved physicians.
- To assess the tolerability profile of TCZ sc under real-world conditions of use.
- To describe the quality of life (QoL) in patients receiving TCZ sc under real-world conditions of use.